Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy (vol 11, 621992, 2021)
FRONTIERS IN ONCOLOGY（2023）
关键词
non-small cell lung cancer, liquid biopsy, gene sequencing, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), drug resistance
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要